---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-071528"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:14:42.053437+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Soleno posts Q4 2025 product revenue of $91.7M; full-year net income $20.9M from VYKAT XR launch

## Summary
- FY 2025 net income $20.9M ($0.40 basic EPS) vs. net loss of $175.9M in 2024.
- Q4 2025 product revenue $91.7M; full-year revenue $190.4M from VYKAT XR (diazoxide choline).
- 859 active patients on drug as of Dec 31, 2025; 1,250 patient start forms received since approval.
- Cash, cash equivalents and marketable securities $506.1M at year end; $100M share repurchase executed.
- First commercial milestone ($7.0M) achieved in Q4 2025; payment due Q1 2026.

## SEC filing metadata
- accession: 0001193125-26-071528
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312526071528/0001193125-26-071528-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312526071528/d251192d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-071528
- JSON: https://secwatch.observer/filing/0001193125-26-071528.json
- Plain text: https://secwatch.observer/filing/0001193125-26-071528.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.